For stage 3A non-small cell lung cancer (NSCLC), the remission rates can vary based on several factors, including the specific treatments received. Here are some key points from my knowledge base:
- Surgery (Lobectomy): Removing the tumor surgically is a common first step
- Chemotherapy: Often used to kill any remaining Show Full Answer
For stage 3A non-small cell lung cancer (NSCLC), the remission rates can vary based on several factors, including the specific treatments received. Here are some key points from my knowledge base:
- Surgery (Lobectomy): Removing the tumor surgically is a common first step.
- Chemotherapy: Often used to kill any remaining cancer cells.
- Targeted Therapy (Tagrisso): Used for tumors with EGFR mutations, can help in prolonging progression-free survival.
While specific remission rates aren't provided, it's important to note that targeted therapies like Tagrisso have shown to increase progression-free survival. For instance, a study mentioned in my knowledge base showed a median progression-free survival of 18.9 months for people with non-small cell lung adenocarcinoma treated with targeted therapy.
Your oncologist can provide more personalized information based on your specific case and treatment response.
November 30, 2024